Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > January 12, 2023
Daily News
January 12, 2023
- Alfresa Sets Up Regenerative Medicine Unit to Supply Master Cells, Eyes Distribution
January 12, 2023
- PMP, Off-Patent Drug Rules to Be Major Topics for 2024 Reform: MHLW Pharma Management Director
January 12, 2023
- Kaken, Axcelead Hook Up on New Drug Discovery
January 12, 2023
- ALS Patient Group Petitions for Early Approval of Relyvrio in Japan
January 12, 2023
- Mitsubishi Tanabe to End Sales of Lexapro as Deal Expires
January 12, 2023
- Japan to Boost Review of Health Damage Claims for COVID-19 Vaccines
January 12, 2023
- 4 Cases of New COVID Variant XBB.1.5 Confirmed in Japan: Govt
January 12, 2023
- Takatsugu Den Tapped as Biogen Japan’s New President
January 12, 2023
- Opdivo Extends Best-Selling Streak to 12 Months: Encise
January 12, 2023
- Eisai Files Alzheimer’s Med Lecanemab in Europe
January 12, 2023
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…